Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Viatris faces downside risk from regulatory challenges, macro headwinds, and muted growth. Click to learn more on why VTRS ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

MHRA is examining whether those affected have a genetic trait that is leaving them at a greater risk of side effects from the ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...

Interpol cited a concerning rise in demand for unauthorised weight loss drugs and peptide supplements in Europe and other ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.